Drug Profile
Research programme: anti-cancer peptides - Avixgen
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator Avixgen
- Class Peptides
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in South Korea (Parenteral)
- 01 Aug 2016 Preclinical trials in Cancer in South Korea (Parenteral)